726 B. K. Nanjwade et al.: [32] Abrams LS, Weintraub HS, Patrick JE, McGuire JL. Comparative bioavailability of lipophilic steroid. J Pharm Sci. 1978; 6: 1287–1290. http://dx.doi.org/10.1002/jps.2600670925 [33] Yamoka Y, Robert RD, Stella VJ. Low melting phenytoin prodrugs as alternative oral delivery modes for phenytoin: A model for other high melting sparingly water soluble drugs. J Pharm Sci. 1983; 72: 400–405. http://dx.doi.org/10.1002/jps.2600720420 [34] Stella V, Haslam J, Yata N, Okada H, Lindenbaum S, Higuchi T. Enhancement of bioavailability of a hydrophobic amine antimalarial by formulation with oleic acid in a soft gelatin capsule. J Pharm Sci. 1978; 67: 1375–1377. http://dx.doi.org/10.1002/jps.2600671011 [35] Tokumura T, Tatsuishi K, Kayano M, Machida Y, Nagai T. Enhancement of oral bioavailability of cinnarizine in oleic acid in beagle dogs. J Pharm Sci. 1987; 76: 286–288. http://dx.doi.org/10.1002/jps.2600760404 [36] Patton TF. Effect of various vehicles and vehicles volumes on oral absorption of triamterene in rats. J Pharm Sci.1981; 70: 1131–1134. http://dx.doi.org/10.1002/jps.2600701010 [37] Myers RA. Systemic bioavailability of penclomedine from oil in water emulsion administer intraduodenally to rats. Int J Pharm. 1992; 78: 217–226. http://dx.doi.org/10.1016/0378-5173(92)90374-B [38] Mehnert W, Mader K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2001; 47: 165–196. http://dx.doi.org/10.1016/S0169-409X(01)00105-3 [39] Zeng XM, Martin GP, Marriott C. The controlled delivery of drugs to the lung. Int J Pharm. 1995; 124: 149–164. http://dx.doi.org/10.1016/0378-5173(95)00104-Q [40] Barratt GM. Therapeutic applications of colloidal drug carriers. Pharm Sci Technol Today. 2000; 3: 163–171. http://dx.doi.org/10.1016/S1461-5347(00)00255-8 [41] Sharma A, Sharma US. Liposomes in drug delivery: Progress and limitations. Int J Pharm. 1997; 154: 123–140. http://dx.doi.org/10.1016/S0378-5173(97)00135-X [42] Manosroi A, Kongkaneramit L, Manosroi J. Stability and transdermal absorption of topical amphotericin B liposome formulations. Int J Pharm. 2004; 270: 279–286. http://dx.doi.org/10.1016/j.ijpharm.2003.10.031 [43] Brannon PL. Recent advances on the use of biodegradable microparticles and nanoparticles in controlled drug delivery. Int J Pharm. 1995; 116: 1–9. http://dx.doi.org/10.1016/0378-5173(94)00324-X Sci Pharm. 2011; 79: 705–727